Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner flush could boost tumor biopsy success

NCT ID NCT05041335

Diagnosis Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the sample. Adults with a solid abdominal mass scheduled for this biopsy, or who had an inconclusive prior biopsy, may join. Participants are randomly assigned to have their needle flushed with heparin or saline, and to have the microsieve used or not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
heparin flush of the biopsy needle
What this could lead to
If it works, this could give doctors a simple way to collect more usable tissue during biopsies, which may lead to faster and more accurate cancer diagnoses.
What could go wrong
This is a small, early study with no guarantee that heparin improves sample quality. Heparin can increase bleeding risk, so patients with low platelets or high INR are excluded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Nov 2025

An estimate. Start dates often move.

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 year * Non-pregnant Patients * Patients with the presence of a solid abdominal mass as seen on diagnostic imaging \[ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)\] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA/FNB for solid pancreatic mass and did not receive a conclusive diagnosis * Patients with platelet count \> 50,000 * Patients with International Normalized Ratio (INR) \< 1.5 Exclusion Criteria: * Age \< 18 years * Pregnant Patients * Patients who cannot consent for themselves * Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days * Patients with cystic abdominal masses * Patients with a platelet count \< 50,000 * Patients with an INR \> 1.5 * Patients with a heparin or porcine allergy * Patients with prior heparin induced thrombocytopenia (HIT) * Patient's with religious aversion to porcine-containing products

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma of liver and intrahepatic biliary tract esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm Liver Neoplasms malignant pancreatic neoplasm neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Cancer of esophagus Cancer of liver Cancer of pancreas Cancer of stomach

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.